1.Innate and adaptive T cells in influenza disease.
Simone NÜSSING ; Sneha SANT ; Marios KOUTSAKOS ; Kanta SUBBARAO ; Thi H O NGUYEN ; Katherine KEDZIERSKA
Frontiers of Medicine 2018;12(1):34-47
Influenza is a major global health problem, causing infections of the respiratory tract, often leading to acute pneumonia, life-threatening complications and even deaths. Over the last seven decades, vaccination strategies have been utilized to protect people from complications of influenza, especially groups at high risk of severe disease. While current vaccination regimens elicit strain-specific antibody responses, they fail to generate cross-protection against seasonal, pandemic and avian viruses. Moreover, vaccines designed to generate influenza-specific T-cell responses are yet to be optimized. During natural infection, viral replication is initially controlled by innate immunity before adaptive immune responses (T cells and antibody-producing B cells) achieve viral clearance and host recovery. Adaptive T and B cells maintain immunological memory and provide protection against subsequent infections with related influenza viruses. Recent studies also shed light on the role of innate T-cells (MAIT cells, γδ cells, and NKT cells) in controlling influenza and linking innate and adaptive immune mechanisms, thus making them attractive targets for vaccination strategies. We summarize the current knowledge on influenza-specific innate MAIT and γδ T cells as well as adaptive CD8 and CD4 T cells, and discuss how these responses can be harnessed by novel vaccine strategies to elicit cross-protective immunity against different influenza strains and subtypes.
Adaptive Immunity
;
Animals
;
Cross Protection
;
Humans
;
Immunity, Innate
;
Influenza Vaccines
;
therapeutic use
;
Influenza, Human
;
immunology
;
Orthomyxoviridae
;
immunology
;
Orthomyxoviridae Infections
;
immunology
;
T-Lymphocytes
;
immunology
;
Vaccination
2.Cross-Protective Immune Responses Elicited by Live Attenuated Influenza Vaccines.
Yonsei Medical Journal 2013;54(2):271-282
The desired effect of vaccination is to elicit protective immune responses against infection with pathogenic agents. An inactivated influenza vaccine is able to induce the neutralizing antibodies directed primarily against two surface antigens, hemagglutinin and neuraminidase. These two antigens undergo frequent antigenic drift and hence necessitate the annual update of a new vaccine strain. Besides the antigenic drift, the unpredictable emergence of the pandemic influenza strain, as seen in the 2009 pandemic H1N1, underscores the development of a new influenza vaccine that elicits broadly protective immunity against the diverse influenza strains. Cold-adapted live attenuated influenza vaccines (CAIVs) are advocated as a more appropriate strategy for cross-protection than inactivated vaccines and extensive studies have been conducted to address the issues in animal models. Here, we briefly describe experimental and clinical evidence for cross-protection by the CAIVs against antigenically distant strains and discuss possible explanations for cross-protective immune responses afforded by CAIVs. Potential barriers to the achievement of a universal influenza vaccine are also discussed, which will provide useful guidelines for future research on designing an ideal influenza vaccine with broad protection without causing pathogenic effects such as autoimmunity or attrition of protective immunity against homologous infection.
Adaptive Immunity
;
Antigens, Viral/immunology
;
*Cross Protection
;
Genome, Viral
;
Humans
;
Immunity, Innate
;
Influenza Vaccines/*immunology/therapeutic use
;
Influenza, Human/*prevention & control
;
Orthomyxoviridae/genetics/immunology
;
Vaccines, Attenuated
3.A novel M2e-multiple antigenic peptide providing heterologous protection in mice.
Feng WEN ; Ji Hong MA ; Hai YU ; Fu Ru YANG ; Meng HUANG ; Yan Jun ZHOU ; Ze Jun LI ; Xiu Hui WANG ; Guo Xin LI ; Yi Feng JIANG ; Wu TONG ; Guang Zhi TONG
Journal of Veterinary Science 2016;17(1):71-78
Swine influenza viruses (SwIVs) cause considerable morbidity and mortality in domestic pigs, resulting in a significant economic burden. Moreover, pigs have been considered to be a possible mixing vessel in which novel strains loom. Here, we developed and evaluated a novel M2e-multiple antigenic peptide (M2e-MAP) as a supplemental antigen for inactivated H3N2 vaccine to provide cross-protection against two main subtypes of SwIVs, H1N1 and H3N2. The novel tetra-branched MAP was constructed by fusing four copies of M2e to one copy of foreign T helper cell epitopes. A high-yield reassortant H3N2 virus was generated by plasmid based reverse genetics. The efficacy of the novel H3N2 inactivated vaccines with or without M2e-MAP supplementation was evaluated in a mouse model. M2e-MAP conjugated vaccine induced strong antibody responses in mice. Complete protection against the heterologous swine H1N1 virus was observed in mice vaccinated with M2e-MAP combined vaccine. Moreover, this novel peptide confers protection against lethal challenge of A/Puerto Rico/8/34 (H1N1). Taken together, our results suggest the combined immunization of reassortant inactivated H3N2 vaccine and the novel M2e-MAP provided cross-protection against swine and human viruses and may serve as a promising approach for influenza vaccine development.
Animals
;
Antibodies, Viral/blood
;
Antigens, Viral/genetics/*immunology
;
Body Weight
;
Cross Protection/*immunology
;
Disease Models, Animal
;
Epitopes, T-Lymphocyte/genetics/immunology
;
Female
;
Influenza A Virus, H3N2 Subtype/genetics/*immunology
;
Influenza Vaccines/*immunology
;
Mice
;
Mice, Inbred BALB C
;
Orthomyxoviridae Infections/*immunology/mortality/pathology/prevention & control
;
Peptides/genetics/*immunology
;
Random Allocation
;
Survival Analysis
;
Vaccines, Synthetic/immunology
;
Virus Replication
4.Immunogenicity and heterologous protection in mice with a recombinant adenoviral-based vaccine carrying a hepatitis C virus truncated NS3 and core fusion protein.
Jie GUAN ; Yao DENG ; Hong CHEN ; Yang YANG ; Bo WEN ; Wenjie TAN
Chinese Journal of Virology 2015;31(1):7-13
To develop a safe and broad-spectrum effective hepatitis C virus (HCV) T cell vaccine,we constructed the recombinant adenovirus-based vaccine that carried the hepatitis C virus truncated NS3 and core fusion proteins. The expression of the fusion antigen was confirmed by in vitro immunofluorescence and western blotting assays. Our results indicated that this vaccine not only stimulated antigen-specific antibody responses,but also activated strong NS3-specific T cell immune responses. NS3-specific IFN-γ+ and TNF-α+ CD4+ T cell subsets were also detected by a intracellular cytokine secretion assay. In a surrogate challenge assay based on a recombinant heterologous HCV (JFH1,2a) vaccinia virus,the recombinant adenovirus-based vaccine was capable of eliciting effective levels of cross-protection. These findings have im- portant implications for the study of HCV immune protection and the future development of a novel vaccine.
Adenoviridae
;
genetics
;
metabolism
;
Animals
;
CD4-Positive T-Lymphocytes
;
immunology
;
Cross Protection
;
Female
;
Genetic Vectors
;
biosynthesis
;
genetics
;
Hepacivirus
;
genetics
;
immunology
;
Hepatitis C
;
immunology
;
prevention & control
;
virology
;
Humans
;
Interferon-gamma
;
immunology
;
Mice
;
Mice, Inbred BALB C
;
Recombinant Proteins
;
administration & dosage
;
genetics
;
immunology
;
Viral Core Proteins
;
administration & dosage
;
genetics
;
immunology
;
Viral Hepatitis Vaccines
;
administration & dosage
;
genetics
;
immunology
;
Viral Nonstructural Proteins
;
administration & dosage
;
genetics
;
immunology
5.Evaluation of influenza A virus nucleoprotein based on baculovirus surface-display technology.
Li-Xia ZHANG ; Jian-Fang ZHOU ; Zai-Jiang YU ; Yue-Long SHU
Chinese Journal of Virology 2013;29(3):265-272
Nucleoprotein (NP) of influenza virus is highly conserved and type-specific. NP can trigger strong cell-mediated immune responses in host and is involved in the protection against the challenges with different subtype influenza viruses. Here, NP of an avian H5N1 (A/Hubei/1/2010, HB) was expressed by baculovirus surface-display technology and its immunogenicity as well as protective mechanism was investigated in mice infection model. Western blot and immunolabeled electron microscopy assay showed NP was displayed on baculovirus surface. ELISA results showed NP could induce high level of anti-NP IgG in the sera from NP-Bac-inoculated mice. Two cellular immune peptides (NP57-74 IQNSITIERMVLSAFDER and NP441-458 RTEIIKMMESARPEDLSF) were identified by IFN-gamma ELISPOT assay. NP57-66 and NP441-450 and NP protein could be able to trigger the activation of CD4+ and CD8+ T cells, and the response of CD8+ T was more predominant. The challenge study of mice-adapted virus A/PR/8/34 (H1N1) showed that NP-Bac could reduce viral load and attenuate the damage to lung tissue. 50% protection ratio against the virus could be detected.
Animals
;
Antibodies, Viral
;
immunology
;
Baculoviridae
;
genetics
;
metabolism
;
Cross Protection
;
Enzyme-Linked Immunospot Assay
;
Female
;
Humans
;
Immunity, Cellular
;
Influenza A Virus, H1N1 Subtype
;
genetics
;
immunology
;
Influenza A Virus, H5N1 Subtype
;
genetics
;
immunology
;
Influenza, Human
;
immunology
;
virology
;
Mice
;
Mice, Inbred BALB C
;
RNA-Binding Proteins
;
genetics
;
immunology
;
T-Lymphocytes
;
immunology
;
Viral Core Proteins
;
genetics
;
immunology